Effects of etoposide alone and in combination with piroxicam on canine osteosarcoma cell lines

Vet J. 2016 Dec:218:51-59. doi: 10.1016/j.tvjl.2016.11.007. Epub 2016 Nov 16.

Abstract

Osteosarcoma (OSA) is the most common primary bone tumour in dogs. The poor survival rate in dogs with OSA highlights the need for new therapeutic approaches. This study evaluated the cytotoxic effects of etoposide, alone and in combination with piroxicam, on canine OSA cell cultures. Etoposide alone significantly suppressed cell growth and viability, whereas etoposide in combination with piroxicam exhibited concentration dependent cytotoxicity. The anti-proliferative effect was a result of inactivity of the Cdc2-cyclin B1 complex, which correlated with an increase in the G2/M fraction. This subsequently activated the apoptosis cascade, as indicated by elevated apoptosis levels and up-regulation of poly (ADP-ribose) polymerase proteolytic cleavage. Down-regulation of survivin expression induced by the combination treatment may have contributed to the enhanced cytotoxicity. The results of this study suggest that further investigation of etoposide and piroxicam as a therapeutic combination for canine OSA is warranted.

Keywords: Apoptosis; Canine osteosarcoma; Etoposide; Piroxicam; Survivin.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis / drug effects
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / veterinary*
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Dog Diseases / drug therapy*
  • Dogs
  • Down-Regulation / drug effects
  • Etoposide / pharmacology*
  • Osteosarcoma / drug therapy
  • Osteosarcoma / veterinary*
  • Piroxicam / pharmacology*
  • Up-Regulation / drug effects

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents, Phytogenic
  • Piroxicam
  • Etoposide